Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00923663|
Recruitment Status : Unknown
Verified September 2010 by Medical University of Vienna.
Recruitment status was: Recruiting
First Posted : June 18, 2009
Last Update Posted : September 28, 2010
|Condition or disease||Intervention/treatment||Phase|
|MALT Lymphoma||Drug: Lenalidomide||Phase 2|
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma.
The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|
|Study Start Date :||July 2009|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||June 2011|
Lenalidomide administered orally at a dose of 25 mg daily
25 mg Lenalidomide p.o. daily for 21 days
- Rate of objective responses induced by Lenalidomide [ Time Frame: 24 months ]
- Time to progression [ Time Frame: 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00923663
|Contact: Markus Raderer, MD||+43-1-40400 ext email@example.com|
|Dept of Internal Medicine||Recruiting|
|Vienna, Austria, A-1090|
|Contact: Markus Raderer, MD +43-1-40400 ext 2296 firstname.lastname@example.org|
|Principal Investigator: Markus Raderer, MD|